Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teniposide + Bu/Cy Conditioning for CNS-HLH HSCT
NCT06048107Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Oct 2023
- Primary completion
- Sep 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of teniposide in hemophagocytic lymphohistiocytosis (HLH), sponsored by Beijing Friendship Hospital. Primary endpoint: The clinical remission rate at 24 weeks. Status: unknown.
02
Drugs
teniposide
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT06048107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048107.